Liver Biomarkers in Anorexia Nervosa (LIBAN)

Nantes University Hospital (NUH)

Status: Enrolling

Conditions: Anorexia Nervosa

Treatments: Diagnostic Test: Fibroscan

Study type: Observational

Funder types: Other

Identifiers

NCT05861375

RC23_0049

Details and patient eligibility

About

The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.

Full description

Prevalence of hepatic fibrosis will be non-invasively investigated, in the Anorexia Nervosa inpatient population, using the Fibroscan ®. Furthermore, liver blood markers will be assessed.

Enrollment: 50 estimated patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria :

• Patient over 15 years old
• Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
• Admission to the endocrinology, diabetology and nutrition department of the Nantes University Hospital.

Exclusion Criteria :

• Chronic active viral hepatitis
• Hemochromatosis
• Other genetic, autoimmune, toxic or drug-induced hepatitis
• Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months
• Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)

Trial design

50 participants in 1 patient group

Non applicable (NA)

Description:

Patients with Anorexia Nervosa hospitalized for malnutrition

Treatment:

Diagnostic Test: Fibroscan